Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology

This study has been terminated.
(Enrollment considerations and current status of the clinical study)
Information provided by (Responsible Party):
Cook Identifier:
First received: October 17, 2013
Last updated: December 22, 2014
Last verified: December 2014
To assess the adequacy of an endometrial biopsy sample obtained using sonohysterography.

Condition Intervention
Endometrial Neoplasms
Polycystic Ovary Syndrome
Uterine Neoplasms
Device: SonoBiopsy Catheter
Device: Endometrial biopsy catheter

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Official Title: Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology

Resource links provided by NLM:

Further study details as provided by Cook:

Primary Outcome Measures:
  • percentage of adequate endometrial biopsies utilizing sonohysterography [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • percentage of adequate endometrial biopsies collected without sonohysterography [ Time Frame: 7 days ] [ Designated as safety issue: No ]

Enrollment: 2
Study Start Date: October 2013
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SonoBiopsy Catheter Device: SonoBiopsy Catheter
Catheter utilized in dual role: sonohysterography and endometrial biopsy
Other Name: Endometrial biopsy with sonohysterography
Active Comparator: Endometrial biopsy catheter Device: Endometrial biopsy catheter
Endometrial sample obtained without the assistance of sonohysterography
Other Name: Endometrial biopsy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with thickened endometrium
  • Abnormal uterine bleeding

Exclusion Criteria:

  • Pregnant
  • Active pelvic infection
  • Pelvic inflammatory disease
  • Blood clotting disorders
  • Sexually transmitted disease
  • Uterine perforation
  • Recent cesarean section
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01969396

Hospital Punta Pacifica
Panama City, Panama, 8C6Q1 JGW8N
Sponsors and Collaborators
Principal Investigator: Ricardo Mastellari, MD Hospital Punta Pacifica
  More Information

Responsible Party: Cook Identifier: NCT01969396     History of Changes
Other Study ID Numbers: 12-012 
Study First Received: October 17, 2013
Last Updated: December 22, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Cook:
Endometrial biopsy
Endometrial sampling

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Endometrial Neoplasms
Uterine Neoplasms
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Uterine Hemorrhage
Uterine Diseases
Menstruation Disturbances
Pathologic Processes
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site processed this record on October 25, 2016